Licia Rivoltini

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  2. ncbi request reprint Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?
    Licia Rivoltini
    Istituto Nazionale Tumori, ViaVenezian 1, 20133 Milan, Italy
    Expert Opin Biol Ther 5:463-76. 2005
  3. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 9:32. 2011
  4. pmc A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
    Lisa H Butterfield
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
    J Transl Med 6:81. 2008
  5. pmc Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology
    Hideaki Tahara
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    J Transl Med 7:45. 2009
  6. pmc Proton dynamics in cancer
    Veronica Huber
    Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    J Transl Med 8:57. 2010
  7. ncbi request reprint Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine
    Paola Filipazzi
    Unit of Immunotherapy of Human Tumors and Unit of Medical Statistics and Biometry, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 25:2546-53. 2007
  8. ncbi request reprint Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity
    Chiara Casati
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 66:4450-60. 2006
  9. ncbi request reprint Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96
    Lorenzo Pilla
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 65:3942-9. 2005
  10. doi request reprint LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites
    Chiara Camisaschi
    Unit of Immunotherapy of Human Tumors, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milan, Italy
    J Immunol 184:6545-51. 2010

Collaborators

Detail Information

Publications29

  1. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  2. ncbi request reprint Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?
    Licia Rivoltini
    Istituto Nazionale Tumori, ViaVenezian 1, 20133 Milan, Italy
    Expert Opin Biol Ther 5:463-76. 2005
    ....
  3. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 9:32. 2011
    ..Four topics of discussion were identified: New pathways in Melanoma, Biomarkers, Clinical Trials and New Molecules and Strategies...
  4. pmc A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
    Lisa H Butterfield
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
    J Transl Med 6:81. 2008
    ..This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document...
  5. pmc Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology
    Hideaki Tahara
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    J Transl Med 7:45. 2009
    ..The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions...
  6. pmc Proton dynamics in cancer
    Veronica Huber
    Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    J Transl Med 8:57. 2010
    ....
  7. ncbi request reprint Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine
    Paola Filipazzi
    Unit of Immunotherapy of Human Tumors and Unit of Medical Statistics and Biometry, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 25:2546-53. 2007
    ....
  8. ncbi request reprint Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity
    Chiara Casati
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 66:4450-60. 2006
    ....
  9. ncbi request reprint Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96
    Lorenzo Pilla
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 65:3942-9. 2005
    ..Altogether, these findings identify the activation of the NK compartment as an additional immunologic effect of autologous tumor-derived HSP96 administration in cancer patients...
  10. doi request reprint LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites
    Chiara Camisaschi
    Unit of Immunotherapy of Human Tumors, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milan, Italy
    J Immunol 184:6545-51. 2010
    ..Our data show that LAG-3 defines an active CD4(+)CD25(high)Foxp3(+) regulatory T cell subset whose frequency is enhanced in the PBMCs of patients with cancer and is expanded at tumor sites...
  11. doi request reprint Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?
    Manuela Iero
    Unit of Immunotherapy of Human Tumours, Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    Cancer Immunol Immunother 58:1159-67. 2009
    ..Considering the results presently achieved with this vaccine approach, and the emerging availability of alternative strategies for boosting anti-tumour immunity, the use of modified tumour peptides could be reconsidered...
  12. ncbi request reprint A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients
    Lorenzo Pilla
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Cancer Immunol Immunother 55:958-68. 2006
    ..Clinical activity was limited to SD. However, both immunological and clinical responses were not improved as compared with those recorded in a previous study investigating HSPPC-96 monotherapy...
  13. ncbi request reprint Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes
    Roberta Valenti
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 66:9290-8. 2006
    ..Therapeutic interventions on the crucial steps of this pathway may contribute to restore tumor/immune system interactions favoring T-cell-mediated control of tumor growth in cancer patients...
  14. ncbi request reprint NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients
    Cristina Maccalli
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Clin Cancer Res 13:7459-68. 2007
    ..The role of NKG2D receptor in antitumor immunosurveillance has not been completely clarified. We addressed this issue by investigating the involvement of this receptor in tumor-specific immunologic response in melanoma patients...
  15. ncbi request reprint Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens
    Diego Tosi
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    J Immunol 172:5363-70. 2004
    ..Together, our data suggest that the ability of IFN-DCs to efficiently prime anti-tumor CD8(+) T lymphocytes relied mostly on the positive cross-talk occurring between DCs and NK cells upon stimulation with IFN-alpha...
  16. ncbi request reprint Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape
    Veronica Huber
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Gastroenterology 128:1796-804. 2005
    ....
  17. ncbi request reprint Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues
    Matteo G Carrabba
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, 20133 Milan, Italy
    Cancer Res 63:1560-7. 2003
    ....
  18. ncbi request reprint Vaccination: role in metastatic melanoma
    Lorenzo Pilla
    Istituto Nazionale per lo Studio e la Cura dei Tumori, Unit of Immunotherapy of Human Tumors, Via Venezian 1, 20133 Milan, Italy
    Expert Rev Anticancer Ther 6:1305-18. 2006
    ....
  19. ncbi request reprint Heat shock proteins and their use as anticancer vaccines
    Giorgio Parmiani
    Istituto Nazionale Tumori, Milan, Italy
    Clin Cancer Res 10:8142-6. 2004
  20. ncbi request reprint Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction
    Licia Rivoltini
    Units of Human Tumor Immunotherapy and Immunobiology, Istituto Nazionale Tumori, Milan, Italy
    Immunol Rev 188:97-113. 2002
    ..Finally, we discuss the role of inducible nitric oxide synthases in determining the inhibition of apoptosis in melanoma cells, which can make such tumor cells resistant to the T-cell attack...
  21. ncbi request reprint Heat shock proteins gp96 as immunogens in cancer patients
    Giorgio Parmiani
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Int J Hyperthermia 22:223-7. 2006
    ....
  22. ncbi request reprint Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen
    Monica Rodolfo
    Units of Melanoma Genetics, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy
    Cancer Res 63:6948-55. 2003
    ..We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy...
  23. ncbi request reprint Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer
    Vincenzo Mazzaferro
    Units of Hepatobiliary and Gastro Pancreatic Surgery, Istituto Nazionale per lo Studio e la Cura Tumori, 20133 Milan, Italy
    Clin Cancer Res 9:3235-45. 2003
    ..Feasibility, safety, and possible clinical benefits were also evaluated...
  24. ncbi request reprint The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients
    Chiara Casati
    Unit of Immunotherapy of Human Tumors, Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian 1, 20133 Milan, Italy
    Cancer Res 63:4507-15. 2003
    ..These findings indicate that survivin could be considered a valuable tumor-associated antigen for immune-based clinical approaches in colorectal cancer...
  25. ncbi request reprint Vaccination therapy in prostate cancer
    Andrea Marrari
    Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, 20133 Milan, Italy
    Cancer Immunol Immunother 56:429-45. 2007
    ..In some cases clinical responses were achieved showing that vaccine-primed T cells induced anti-tumour activity in vivo. The present findings and perspectives of the immunologic interventions in PC patients will be discussed...
  26. ncbi request reprint Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells
    Piero Dalerba
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 65:2321-9. 2005
    ..Taken together, our data show that, in a least subset of CRC, biochemical pathways involved in maintenance of telomere length, such as telomerase, are not activated in a constitutive way in all tumor cells...
  27. ncbi request reprint Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts
    Michelandrea De Cesare
    Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    Eur J Cancer 41:1213-22. 2005
    ..The capability of oblimersen to improve the efficacy of gimatecan supports the therapeutic potential of the drug combination in the treatment of human melanoma...
  28. doi request reprint Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy
    Valentina Ciravolo
    Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
    J Cell Physiol 227:658-67. 2012
    ..Together, these findings point to the role of HER2-positive exosomes in modulating sensitivity to Trastuzumab, and, consequently, to HER2-driven tumor aggressiveness...
  29. ncbi request reprint Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings
    Filiberto Belli
    Unit of General Surgery 2, Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 20:4169-80. 2002
    ....